Argenx SE (NASDAQ:ARGX) stock jumped about 12% in Monday’s premarket trading after the company reported positive topline results from its Phase 3 ALKIVIA study.
The trial evaluated VYVGART Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with autoimmune myositis.